This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zacks Industry Outlook Highlights: Amgen, ANI and Illumina
by Zacks Equity Research
Zacks Industry Outlook Highlights: Amgen, ANI and Illumina
Biotech Stock Outlook: Short-Term Pricing Pain to Prevail
by Zacks Equity Research
Decline in sales of high-profile drugs, pipeline setbacks and competitive pressure are likely to adversely impact the overall performance of the biotech sector in the short term.
Alkermes' Aristada Initio Approved by FDA for Schizophrenia
by Zacks Equity Research
FDA approves Alkermes' (ALKS) Aristada Initio (aripiprazole lauroxil) for the treatment of schizophrenia in adults.
Roche's Breast Cancer Study Meets Co-Primary Endpoint
by Zacks Equity Research
Phase III IMpassion130 study shows that Roche???s (RHHBY) Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer.
Should You Invest in the ARK Genomic Revolution Multi-Sector ETF (ARKG)?
by Zacks Equity Research
Sector ETF report for ARKG
AMGN or ILMN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMGN vs. ILMN: Which Stock Is the Better Value Option?
Genomics Market Gains Momentum: 3 DNA Stocks in Focus
by Nabaparna Bhattacharya
Here we discuss about how Genomics creates opportunities in MedTech for investors who are keen on putting money in the healthcare space.
Is Illumina (ILMN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is Illumina, Inc. (ILMN) Outperforming Other Medical Stocks This Year?
Novo Nordisk (NVO) Announces Results in Diabetes Studies
by Zacks Equity Research
Novo Nordisk (NVO) announces results from a number of studies being evaluated to treat diabetes.
Zacks.com featured highlights include: Illumina, Lululemon, Surmodics and ConocoPhillips
by Zacks Equity Research
Zacks.com featured highlights include: Illumina, Lululemon, Surmodics and ConocoPhillips
Anika Reports Top Line Data from CINGAL Study, Shares Slump
by Zacks Equity Research
Anika Therapeutics' (ANIK) shares declined 37%, after the company reported disappointing data from its phase III Cingal 16-02 study in treating patients with osteoarthritis (OA) in the knee.
4 of the Best Efficient Stocks to Buy for Superb Returns
by Tirthankar Chakraborty
We have considered four popular ratios in order to find efficient companies that have the potential to provide impressive returns
Novo Nordisk in Deal with Kallyope for Obesity, Diabetes Drugs
by Zacks Equity Research
Novo Nordisk (NVO) enters into a research collaboration and option agreement with Kallyope, Inc. to develop novel therapies for diabetes and obesity.
Alexion (ALXN) Submits Application for ALXN1210 with FDA
by Zacks Equity Research
Alexion Pharmaceuticals, Inc. (ALXN) submits a Biologics License Application (BLA) to the FDA for approval of ALXN1210 to treat patients with paroxysmal nocturnal hemoglobinuria (PNH).
Walgreens Boots' Retail Pharmacy Strong Despite Several Woes
by Zacks Equity Research
Walgreens Boots' (WBA) consistent sales rise in the Retail Pharmacy International business is encouraging. Moreover, the company steadily gains traction from a slew of strategic deals.
BSX or BAX: Which is a Better Pick for Your Portfolio Now?
by Zacks Equity Research
After considering various parameters and fundamentals, we help you make a choice between Boston Scientific (BSX) and Baxter (BAX).
Valeant Down as FDA Refuses to Approve Duobrii For Psoriasis
by Zacks Equity Research
Valeant (VRX) suffers a setback as the FDA issues a CRL for its plaque psoriasis lotion, Duobrii.
QIAGEN (QGEN) Banks on Molecular Diagnostics, Global Growth
by Zacks Equity Research
QIAGEN's (QGEN) progress with the test menu expansion is impressive. Earlier in Q1, the company also secures the Japanese approval for QuantiFERON-TB Gold Plus as an in vitro diagnostic to detect TB.
Hologic's New Panther Fusion System Gets Health Canada Nod
by Zacks Equity Research
Hologic's (HOLX) receipt of Health Canada approval for the new Panther Fusion system and Panther Fusion assays, for respiratory virus infections, is expected to boost the top line in the near term.
Here's Why You Should Add Amedisys (AMED) to Your Portfolio
by Zacks Equity Research
Amedisys' (AMED) solid performance in the recently launched Personal Care segment buoys optimism. A favorable demographic trend and strategic acquisitions also bode well for the company.
Medtronic's Expanded IN.PACT Admiral FDA Nod to Aid APV Arm
by Zacks Equity Research
Medtronic's (MDT) receipt of FDA approval for 200mm and 250mm lengths of the IN.PACT Admiral Drug-Coated Balloon (DCB) is expected to boost the top line.
Anatomy of Success: Illumina (ILMN)
by Ryan McQueeney
If investors had followed our ranking system when it flagged innovative biotech company, they would have witnessed massive profits.
Dr. Reddy's/Mylan Get FDA Nod for First Generic of Suboxone
by Zacks Equity Research
Dr. Reddy's (RDY) and Mylan announced that the FDA approved the first generic version of Suboxone (Buprenorphine and Naloxone Sublingual Film) under-the-tongue film for the treatment of opioid addiction.
Flex Pharma Down on Workforce Reduction, Ends Phase II Study
by Zacks Equity Research
Flex Pharma (FLKS) announced that the company is ending the phase II studies for its pipeline candidate FLX-787 in two indications. The company also plans to lower its workforce by about 60%.
Roche's (RHHBY) Avastin Gets Label Expansion Approval by FDA
by Zacks Equity Research
Roche (RHHBY) announced that the FDA has approved the label expansion for its oncology drug Avastin in combination with chemotherapy, for the treatment of women with advanced ovarian cancer following initial surgical resection.